nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—myometrium—ovarian cancer	0.0224	0.123	CbGeAlD
Epoprostenol—PTGIS—decidua—ovarian cancer	0.0166	0.0914	CbGeAlD
Epoprostenol—P2RY12—epithelium—ovarian cancer	0.0158	0.0871	CbGeAlD
Epoprostenol—PTGIS—uterus—ovarian cancer	0.0145	0.08	CbGeAlD
Epoprostenol—PTGIS—female reproductive system—ovarian cancer	0.013	0.0719	CbGeAlD
Epoprostenol—PTGER1—female reproductive system—ovarian cancer	0.0121	0.0668	CbGeAlD
Epoprostenol—PTGIS—female gonad—ovarian cancer	0.0119	0.0654	CbGeAlD
Epoprostenol—PTGER1—female gonad—ovarian cancer	0.011	0.0608	CbGeAlD
Epoprostenol—PTGIS—testis—ovarian cancer	0.0105	0.058	CbGeAlD
Epoprostenol—PTGIR—epithelium—ovarian cancer	0.0101	0.0556	CbGeAlD
Epoprostenol—PTGIR—gonad—ovarian cancer	0.00839	0.0462	CbGeAlD
Epoprostenol—PTGIS—lymph node—ovarian cancer	0.00763	0.0421	CbGeAlD
Epoprostenol—PTGIR—female reproductive system—ovarian cancer	0.00749	0.0413	CbGeAlD
Epoprostenol—PTGIR—female gonad—ovarian cancer	0.00682	0.0376	CbGeAlD
Epoprostenol—PTGIR—testis—ovarian cancer	0.00605	0.0333	CbGeAlD
Epoprostenol—PTGIR—lymph node—ovarian cancer	0.00438	0.0242	CbGeAlD
Epoprostenol—CYP2C9—female reproductive system—ovarian cancer	0.00268	0.0148	CbGeAlD
Epoprostenol—Nausea—Melphalan—ovarian cancer	0.000711	0.00109	CcSEcCtD
Epoprostenol—Confusional state—Paclitaxel—ovarian cancer	0.000709	0.00109	CcSEcCtD
Epoprostenol—Back pain—Docetaxel—ovarian cancer	0.000706	0.00108	CcSEcCtD
Epoprostenol—Oedema—Paclitaxel—ovarian cancer	0.000703	0.00108	CcSEcCtD
Epoprostenol—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000703	0.00108	CcSEcCtD
Epoprostenol—Muscle spasms—Docetaxel—ovarian cancer	0.000702	0.00107	CcSEcCtD
Epoprostenol—Infection—Paclitaxel—ovarian cancer	0.000699	0.00107	CcSEcCtD
Epoprostenol—Shock—Paclitaxel—ovarian cancer	0.000692	0.00106	CcSEcCtD
Epoprostenol—Dizziness—Vinorelbine—ovarian cancer	0.000691	0.00106	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000691	0.00106	CcSEcCtD
Epoprostenol—Nervous system disorder—Paclitaxel—ovarian cancer	0.00069	0.00106	CcSEcCtD
Epoprostenol—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000688	0.00105	CcSEcCtD
Epoprostenol—Tachycardia—Paclitaxel—ovarian cancer	0.000686	0.00105	CcSEcCtD
Epoprostenol—Skin disorder—Paclitaxel—ovarian cancer	0.000683	0.00105	CcSEcCtD
Epoprostenol—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00068	0.00104	CcSEcCtD
Epoprostenol—Anaemia—Docetaxel—ovarian cancer	0.000675	0.00103	CcSEcCtD
Epoprostenol—Pancytopenia—Epirubicin—ovarian cancer	0.000671	0.00103	CcSEcCtD
Epoprostenol—Anorexia—Paclitaxel—ovarian cancer	0.00067	0.00103	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—ovarian cancer	0.00067	0.00103	CcSEcCtD
Epoprostenol—Vomiting—Vinorelbine—ovarian cancer	0.000665	0.00102	CcSEcCtD
Epoprostenol—Rash—Vinorelbine—ovarian cancer	0.000659	0.00101	CcSEcCtD
Epoprostenol—Dermatitis—Vinorelbine—ovarian cancer	0.000659	0.00101	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—ovarian cancer	0.000658	0.00101	CcSEcCtD
Epoprostenol—Hypotension—Paclitaxel—ovarian cancer	0.000657	0.00101	CcSEcCtD
Epoprostenol—Headache—Vinorelbine—ovarian cancer	0.000655	0.001	CcSEcCtD
Epoprostenol—Syncope—Docetaxel—ovarian cancer	0.000655	0.001	CcSEcCtD
Epoprostenol—Palpitations—Docetaxel—ovarian cancer	0.000645	0.000988	CcSEcCtD
Epoprostenol—Loss of consciousness—Docetaxel—ovarian cancer	0.000642	0.000982	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000641	0.000981	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—ovarian cancer	0.00064	0.000979	CcSEcCtD
Epoprostenol—Cough—Docetaxel—ovarian cancer	0.000637	0.000975	CcSEcCtD
Epoprostenol—Insomnia—Paclitaxel—ovarian cancer	0.000636	0.000973	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—ovarian cancer	0.000634	0.00097	CcSEcCtD
Epoprostenol—Paraesthesia—Paclitaxel—ovarian cancer	0.000631	0.000966	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—ovarian cancer	0.00063	0.000965	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—ovarian cancer	0.00063	0.000965	CcSEcCtD
Epoprostenol—Dyspnoea—Paclitaxel—ovarian cancer	0.000627	0.00096	CcSEcCtD
Epoprostenol—Somnolence—Paclitaxel—ovarian cancer	0.000625	0.000957	CcSEcCtD
Epoprostenol—Arthralgia—Docetaxel—ovarian cancer	0.000622	0.000952	CcSEcCtD
Epoprostenol—Chest pain—Docetaxel—ovarian cancer	0.000622	0.000952	CcSEcCtD
Epoprostenol—Myalgia—Docetaxel—ovarian cancer	0.000622	0.000952	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—ovarian cancer	0.000621	0.000951	CcSEcCtD
Epoprostenol—Nausea—Vinorelbine—ovarian cancer	0.000621	0.00095	CcSEcCtD
Epoprostenol—Dyspepsia—Paclitaxel—ovarian cancer	0.000619	0.000947	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000617	0.000945	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—ovarian cancer	0.000613	0.000938	CcSEcCtD
Epoprostenol—Decreased appetite—Paclitaxel—ovarian cancer	0.000611	0.000936	CcSEcCtD
Epoprostenol—Dry mouth—Docetaxel—ovarian cancer	0.000608	0.000931	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000607	0.000929	CcSEcCtD
Epoprostenol—Fatigue—Paclitaxel—ovarian cancer	0.000606	0.000928	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—ovarian cancer	0.000604	0.000925	CcSEcCtD
Epoprostenol—Constipation—Paclitaxel—ovarian cancer	0.000601	0.00092	CcSEcCtD
Epoprostenol—Pain—Paclitaxel—ovarian cancer	0.000601	0.00092	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—ovarian cancer	0.000601	0.00092	CcSEcCtD
Epoprostenol—Confusional state—Docetaxel—ovarian cancer	0.000601	0.00092	CcSEcCtD
Epoprostenol—Oedema—Docetaxel—ovarian cancer	0.000596	0.000912	CcSEcCtD
Epoprostenol—Anaphylactic shock—Docetaxel—ovarian cancer	0.000596	0.000912	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—ovarian cancer	0.000594	0.00091	CcSEcCtD
Epoprostenol—Infection—Docetaxel—ovarian cancer	0.000592	0.000906	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—ovarian cancer	0.000592	0.000906	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—ovarian cancer	0.000591	0.000905	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—ovarian cancer	0.000587	0.000898	CcSEcCtD
Epoprostenol—Shock—Docetaxel—ovarian cancer	0.000586	0.000898	CcSEcCtD
Epoprostenol—Nervous system disorder—Docetaxel—ovarian cancer	0.000584	0.000895	CcSEcCtD
Epoprostenol—Thrombocytopenia—Docetaxel—ovarian cancer	0.000584	0.000893	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—ovarian cancer	0.000583	0.000893	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—ovarian cancer	0.000583	0.000893	CcSEcCtD
Epoprostenol—Tachycardia—Docetaxel—ovarian cancer	0.000582	0.00089	CcSEcCtD
Epoprostenol—Skin disorder—Docetaxel—ovarian cancer	0.000579	0.000886	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—ovarian cancer	0.000576	0.000882	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000575	0.00088	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—ovarian cancer	0.000569	0.000871	CcSEcCtD
Epoprostenol—Anorexia—Docetaxel—ovarian cancer	0.000568	0.00087	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—ovarian cancer	0.000567	0.000868	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—ovarian cancer	0.000567	0.000868	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—ovarian cancer	0.000566	0.000866	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—ovarian cancer	0.000563	0.000862	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—ovarian cancer	0.000562	0.00086	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—ovarian cancer	0.000559	0.000856	CcSEcCtD
Epoprostenol—Urticaria—Paclitaxel—ovarian cancer	0.000559	0.000855	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—ovarian cancer	0.000557	0.000853	CcSEcCtD
Epoprostenol—Hypotension—Docetaxel—ovarian cancer	0.000557	0.000852	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—ovarian cancer	0.000556	0.000851	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—ovarian cancer	0.000556	0.000851	CcSEcCtD
Epoprostenol—Abdominal pain—Paclitaxel—ovarian cancer	0.000556	0.000851	CcSEcCtD
Epoprostenol—Body temperature increased—Paclitaxel—ovarian cancer	0.000556	0.000851	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—ovarian cancer	0.00055	0.000842	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—ovarian cancer	0.000547	0.000838	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000543	0.000831	CcSEcCtD
Epoprostenol—Insomnia—Docetaxel—ovarian cancer	0.000539	0.000825	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—ovarian cancer	0.000535	0.000819	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—ovarian cancer	0.000533	0.000816	CcSEcCtD
Epoprostenol—Dyspnoea—Docetaxel—ovarian cancer	0.000531	0.000813	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—ovarian cancer	0.00053	0.000811	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—ovarian cancer	0.000526	0.000805	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—ovarian cancer	0.000525	0.000804	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—ovarian cancer	0.000525	0.000804	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—ovarian cancer	0.000525	0.000803	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—ovarian cancer	0.000525	0.000803	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—ovarian cancer	0.000524	0.000801	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000521	0.000797	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—ovarian cancer	0.00052	0.000795	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—ovarian cancer	0.000518	0.000793	CcSEcCtD
Epoprostenol—Hypersensitivity—Paclitaxel—ovarian cancer	0.000518	0.000793	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—ovarian cancer	0.000516	0.000789	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000515	0.000788	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000514	0.000788	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—ovarian cancer	0.000514	0.000787	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—ovarian cancer	0.000513	0.000786	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—ovarian cancer	0.00051	0.000781	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—ovarian cancer	0.00051	0.00078	CcSEcCtD
Epoprostenol—Pain—Docetaxel—ovarian cancer	0.00051	0.00078	CcSEcCtD
Epoprostenol—Chills—Epirubicin—ovarian cancer	0.000508	0.000777	CcSEcCtD
Epoprostenol—Asthenia—Paclitaxel—ovarian cancer	0.000504	0.000772	CcSEcCtD
Epoprostenol—Pruritus—Paclitaxel—ovarian cancer	0.000497	0.000761	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—ovarian cancer	0.000496	0.000759	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000487	0.000746	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—ovarian cancer	0.000486	0.000744	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—ovarian cancer	0.000486	0.000744	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—ovarian cancer	0.000485	0.000743	CcSEcCtD
Epoprostenol—Tension—Epirubicin—ovarian cancer	0.000483	0.00074	CcSEcCtD
Epoprostenol—Diarrhoea—Paclitaxel—ovarian cancer	0.000481	0.000736	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—ovarian cancer	0.000478	0.000732	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—ovarian cancer	0.000476	0.000729	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—ovarian cancer	0.000475	0.000727	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—ovarian cancer	0.000474	0.000725	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000472	0.000722	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—ovarian cancer	0.000471	0.000721	CcSEcCtD
Epoprostenol—Abdominal pain—Docetaxel—ovarian cancer	0.000471	0.000721	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—ovarian cancer	0.00047	0.000719	CcSEcCtD
Epoprostenol—Dizziness—Paclitaxel—ovarian cancer	0.000465	0.000712	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—ovarian cancer	0.000459	0.000702	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—ovarian cancer	0.000455	0.000697	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—ovarian cancer	0.000453	0.000693	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—ovarian cancer	0.000449	0.000687	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—ovarian cancer	0.000447	0.000685	CcSEcCtD
Epoprostenol—Vomiting—Paclitaxel—ovarian cancer	0.000447	0.000684	CcSEcCtD
Epoprostenol—Rash—Paclitaxel—ovarian cancer	0.000443	0.000679	CcSEcCtD
Epoprostenol—Dermatitis—Paclitaxel—ovarian cancer	0.000443	0.000678	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—ovarian cancer	0.000443	0.000678	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—ovarian cancer	0.000442	0.000676	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—ovarian cancer	0.000441	0.000675	CcSEcCtD
Epoprostenol—Headache—Paclitaxel—ovarian cancer	0.00044	0.000674	CcSEcCtD
Epoprostenol—Hypersensitivity—Docetaxel—ovarian cancer	0.000439	0.000672	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—ovarian cancer	0.000438	0.000671	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—ovarian cancer	0.000435	0.000666	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—ovarian cancer	0.000433	0.000663	CcSEcCtD
Epoprostenol—Cough—Epirubicin—ovarian cancer	0.00043	0.000658	CcSEcCtD
Epoprostenol—Asthenia—Docetaxel—ovarian cancer	0.000428	0.000655	CcSEcCtD
Epoprostenol—Pruritus—Docetaxel—ovarian cancer	0.000422	0.000645	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—ovarian cancer	0.000421	0.000645	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—ovarian cancer	0.000419	0.000642	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—ovarian cancer	0.000419	0.000642	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—ovarian cancer	0.000419	0.000642	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—ovarian cancer	0.000419	0.000641	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—ovarian cancer	0.000418	0.00064	CcSEcCtD
Epoprostenol—Nausea—Paclitaxel—ovarian cancer	0.000418	0.000639	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000416	0.000637	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—ovarian cancer	0.00041	0.000628	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—ovarian cancer	0.000409	0.000626	CcSEcCtD
Epoprostenol—Diarrhoea—Docetaxel—ovarian cancer	0.000408	0.000624	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—ovarian cancer	0.000405	0.00062	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—ovarian cancer	0.000403	0.000616	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—ovarian cancer	0.000402	0.000615	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—ovarian cancer	0.000402	0.000615	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—ovarian cancer	0.000401	0.000613	CcSEcCtD
Epoprostenol—Infection—Epirubicin—ovarian cancer	0.000399	0.000611	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—ovarian cancer	0.000398	0.000609	CcSEcCtD
Epoprostenol—Shock—Epirubicin—ovarian cancer	0.000395	0.000605	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—ovarian cancer	0.000394	0.000603	CcSEcCtD
Epoprostenol—Dizziness—Docetaxel—ovarian cancer	0.000394	0.000603	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—ovarian cancer	0.000394	0.000602	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—ovarian cancer	0.000392	0.000601	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—ovarian cancer	0.00039	0.000598	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—ovarian cancer	0.000389	0.000595	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—ovarian cancer	0.000388	0.000594	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—ovarian cancer	0.000388	0.000594	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—ovarian cancer	0.000388	0.000594	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—ovarian cancer	0.000387	0.000592	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000385	0.00059	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—ovarian cancer	0.000383	0.000587	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—ovarian cancer	0.000379	0.000581	CcSEcCtD
Epoprostenol—Vomiting—Docetaxel—ovarian cancer	0.000379	0.00058	CcSEcCtD
Epoprostenol—Rash—Docetaxel—ovarian cancer	0.000376	0.000575	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—ovarian cancer	0.000376	0.000575	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—ovarian cancer	0.000375	0.000575	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—ovarian cancer	0.000375	0.000574	CcSEcCtD
Epoprostenol—Headache—Docetaxel—ovarian cancer	0.000373	0.000572	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000372	0.000569	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—ovarian cancer	0.000372	0.000569	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—ovarian cancer	0.00037	0.000566	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000366	0.000561	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—ovarian cancer	0.000366	0.00056	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—ovarian cancer	0.000365	0.000558	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000364	0.000557	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—ovarian cancer	0.000364	0.000557	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—ovarian cancer	0.000363	0.000556	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—ovarian cancer	0.000361	0.000553	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—ovarian cancer	0.000361	0.000553	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00036	0.00055	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—ovarian cancer	0.000358	0.000549	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—ovarian cancer	0.000357	0.000547	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—ovarian cancer	0.000355	0.000543	CcSEcCtD
Epoprostenol—Nausea—Docetaxel—ovarian cancer	0.000354	0.000542	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—ovarian cancer	0.000354	0.000542	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—ovarian cancer	0.000349	0.000535	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—ovarian cancer	0.000348	0.000532	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000347	0.000531	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—ovarian cancer	0.000347	0.000531	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—ovarian cancer	0.000344	0.000526	CcSEcCtD
Epoprostenol—Pain—Epirubicin—ovarian cancer	0.000344	0.000526	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000339	0.000519	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—ovarian cancer	0.000336	0.000515	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—ovarian cancer	0.000334	0.000511	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—ovarian cancer	0.000332	0.000508	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—ovarian cancer	0.000331	0.000506	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000329	0.000503	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—ovarian cancer	0.000327	0.000501	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—ovarian cancer	0.000323	0.000495	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000321	0.000492	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—ovarian cancer	0.000321	0.000491	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—ovarian cancer	0.000319	0.000489	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—ovarian cancer	0.000318	0.000487	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—ovarian cancer	0.000318	0.000487	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—ovarian cancer	0.000318	0.000486	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—ovarian cancer	0.000318	0.000486	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000304	0.000466	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—ovarian cancer	0.000296	0.000453	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—ovarian cancer	0.000295	0.000452	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—ovarian cancer	0.000294	0.00045	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—ovarian cancer	0.000294	0.00045	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—ovarian cancer	0.000288	0.000441	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—ovarian cancer	0.000284	0.000435	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—ovarian cancer	0.000275	0.000421	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—ovarian cancer	0.000274	0.000419	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—ovarian cancer	0.000267	0.000408	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—ovarian cancer	0.000266	0.000407	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—ovarian cancer	0.000263	0.000403	CcSEcCtD
Epoprostenol—Vomiting—Epirubicin—ovarian cancer	0.000256	0.000391	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—ovarian cancer	0.000254	0.00039	CcSEcCtD
Epoprostenol—Rash—Epirubicin—ovarian cancer	0.000253	0.000388	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—ovarian cancer	0.000253	0.000388	CcSEcCtD
Epoprostenol—Headache—Epirubicin—ovarian cancer	0.000252	0.000385	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—ovarian cancer	0.000246	0.000377	CcSEcCtD
Epoprostenol—Nausea—Epirubicin—ovarian cancer	0.000239	0.000366	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—ovarian cancer	0.000236	0.000362	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—ovarian cancer	0.000235	0.000359	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—ovarian cancer	0.000234	0.000359	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—ovarian cancer	0.000233	0.000357	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—ovarian cancer	0.000221	0.000338	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—XIAP—ovarian cancer	0.0002	0.00121	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMARCA4—ovarian cancer	0.000194	0.00118	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMARCA4—ovarian cancer	0.000194	0.00118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PGR—ovarian cancer	0.000193	0.00117	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CAV1—ovarian cancer	0.000192	0.00116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EREG—ovarian cancer	0.00019	0.00115	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EREG—ovarian cancer	0.00019	0.00115	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL2—ovarian cancer	0.000186	0.00113	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6ST—ovarian cancer	0.000182	0.0011	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000182	0.0011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.00018	0.00109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PARP1—ovarian cancer	0.00018	0.00109	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PGR—ovarian cancer	0.000178	0.00108	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PGR—ovarian cancer	0.000178	0.00108	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APC—ovarian cancer	0.000175	0.00106	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—ovarian cancer	0.000172	0.00104	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6ST—ovarian cancer	0.000172	0.00104	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NRAS—ovarian cancer	0.00017	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000167	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000167	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PARP1—ovarian cancer	0.000165	0.001	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PARP1—ovarian cancer	0.000165	0.001	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CG—ovarian cancer	0.000165	0.000999	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK3—ovarian cancer	0.000163	0.000984	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CAV1—ovarian cancer	0.000161	0.000974	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CD—ovarian cancer	0.00016	0.000967	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—ovarian cancer	0.000158	0.000958	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6ST—ovarian cancer	0.000158	0.000956	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6ST—ovarian cancer	0.000158	0.000956	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NRAS—ovarian cancer	0.000156	0.000946	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK1—ovarian cancer	0.000155	0.000937	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CD—ovarian cancer	0.000154	0.000931	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	0.000154	0.00093	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CG—ovarian cancer	0.000152	0.000919	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CG—ovarian cancer	0.000152	0.000919	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK3—ovarian cancer	0.00015	0.000906	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000147	0.00089	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000147	0.00089	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CG—ovarian cancer	0.000147	0.000887	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—ovarian cancer	0.000146	0.000885	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PPP2R1A—ovarian cancer	0.000146	0.000881	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CD—ovarian cancer	0.000145	0.000878	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK1—ovarian cancer	0.000143	0.000862	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NME2—ovarian cancer	0.000142	0.000861	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000139	0.000843	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB2—ovarian cancer	0.000136	0.000822	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—ovarian cancer	0.000135	0.000814	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—ovarian cancer	0.000134	0.000813	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTOR—ovarian cancer	0.000134	0.000812	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CB—ovarian cancer	0.000134	0.000812	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PPP2R1A—ovarian cancer	0.000134	0.000811	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PPP2R1A—ovarian cancer	0.000134	0.000811	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL8—ovarian cancer	0.000134	0.00081	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CD—ovarian cancer	0.000134	0.000808	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CD—ovarian cancer	0.000134	0.000808	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—ovarian cancer	0.00013	0.000786	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CD—ovarian cancer	0.000129	0.00078	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000128	0.000775	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000128	0.000775	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—ovarian cancer	0.000128	0.000774	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CB—ovarian cancer	0.000127	0.000765	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1B—ovarian cancer	0.000126	0.000762	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—ovarian cancer	0.000124	0.000752	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—ovarian cancer	0.000124	0.000748	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL8—ovarian cancer	0.000123	0.000745	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL8—ovarian cancer	0.000123	0.000745	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL8—ovarian cancer	0.000122	0.000735	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000121	0.00073	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—ovarian cancer	0.00012	0.000724	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—ovarian cancer	0.000119	0.00072	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—ovarian cancer	0.000118	0.000712	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—ovarian cancer	0.000118	0.000712	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CB—ovarian cancer	0.000116	0.000704	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CB—ovarian cancer	0.000116	0.000704	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—ovarian cancer	0.000116	0.000703	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—ovarian cancer	0.000116	0.000701	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—ovarian cancer	0.000116	0.0007	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—ovarian cancer	0.000114	0.000692	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CB—ovarian cancer	0.000112	0.00068	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—ovarian cancer	0.000112	0.000677	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—ovarian cancer	0.000112	0.000677	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—ovarian cancer	0.00011	0.000664	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CAV1—ovarian cancer	0.000107	0.000648	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—ovarian cancer	0.000107	0.000647	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—ovarian cancer	0.000107	0.000647	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—ovarian cancer	0.000107	0.000644	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—ovarian cancer	0.000107	0.000644	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—ovarian cancer	0.000104	0.000627	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—ovarian cancer	0.000103	0.000626	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ESR1—ovarian cancer	0.000103	0.000624	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6ST—ovarian cancer	0.000102	0.000614	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—ovarian cancer	0.000101	0.000611	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK3—ovarian cancer	9.91e-05	0.000599	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CAV1—ovarian cancer	9.85e-05	0.000596	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CAV1—ovarian cancer	9.85e-05	0.000596	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	9.84e-05	0.000595	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—ovarian cancer	9.75e-05	0.00059	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—ovarian cancer	9.75e-05	0.00059	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—ovarian cancer	9.75e-05	0.00059	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—ovarian cancer	9.71e-05	0.000587	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—ovarian cancer	9.64e-05	0.000583	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ESR1—ovarian cancer	9.5e-05	0.000574	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ESR1—ovarian cancer	9.5e-05	0.000574	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK1—ovarian cancer	9.43e-05	0.00057	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—ovarian cancer	9.42e-05	0.00057	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6ST—ovarian cancer	9.34e-05	0.000565	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6ST—ovarian cancer	9.34e-05	0.000565	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—ovarian cancer	9.34e-05	0.000565	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYTB—ovarian cancer	9.17e-05	0.000555	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—ovarian cancer	8.98e-05	0.000543	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—ovarian cancer	8.98e-05	0.000543	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—ovarian cancer	8.98e-05	0.000543	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—ovarian cancer	8.98e-05	0.000543	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—ovarian cancer	8.98e-05	0.000543	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—ovarian cancer	8.98e-05	0.000543	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	8.96e-05	0.000542	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—ovarian cancer	8.9e-05	0.000539	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK1—ovarian cancer	8.89e-05	0.000538	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—ovarian cancer	8.89e-05	0.000537	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—ovarian cancer	8.6e-05	0.00052	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—ovarian cancer	8.6e-05	0.00052	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—ovarian cancer	8.57e-05	0.000519	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—ovarian cancer	8.49e-05	0.000514	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—ovarian cancer	8.39e-05	0.000508	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—ovarian cancer	8.18e-05	0.000495	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK1—ovarian cancer	8.18e-05	0.000495	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK1—ovarian cancer	8.18e-05	0.000495	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—ovarian cancer	8.18e-05	0.000495	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—ovarian cancer	8.18e-05	0.000495	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPP1CC—ovarian cancer	8.02e-05	0.000485	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BRIP1—ovarian cancer	8.02e-05	0.000485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—ovarian cancer	7.89e-05	0.000477	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—ovarian cancer	7.89e-05	0.000477	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—ovarian cancer	7.82e-05	0.000473	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—ovarian cancer	7.82e-05	0.000473	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—ovarian cancer	7.72e-05	0.000467	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—ovarian cancer	7.72e-05	0.000467	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—ovarian cancer	7.71e-05	0.000466	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—ovarian cancer	7.57e-05	0.000458	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—ovarian cancer	7.57e-05	0.000458	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—ovarian cancer	7.47e-05	0.000452	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MTOR—ovarian cancer	7.47e-05	0.000452	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—ovarian cancer	7.24e-05	0.000438	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—ovarian cancer	7.18e-05	0.000434	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—ovarian cancer	7.13e-05	0.000432	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—ovarian cancer	7.1e-05	0.000429	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—ovarian cancer	7.1e-05	0.000429	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—ovarian cancer	7.01e-05	0.000424	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—ovarian cancer	6.97e-05	0.000422	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—ovarian cancer	6.97e-05	0.000422	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—ovarian cancer	6.94e-05	0.00042	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MTOR—ovarian cancer	6.88e-05	0.000416	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—ovarian cancer	6.88e-05	0.000416	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—ovarian cancer	6.88e-05	0.000416	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MTOR—ovarian cancer	6.88e-05	0.000416	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—ovarian cancer	6.87e-05	0.000416	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—ovarian cancer	6.86e-05	0.000415	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—ovarian cancer	6.85e-05	0.000414	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—ovarian cancer	6.83e-05	0.000413	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—ovarian cancer	6.69e-05	0.000405	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—ovarian cancer	6.68e-05	0.000404	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—ovarian cancer	6.63e-05	0.000401	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—ovarian cancer	6.61e-05	0.0004	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—ovarian cancer	6.61e-05	0.0004	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—ovarian cancer	6.57e-05	0.000397	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—ovarian cancer	6.57e-05	0.000397	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—ovarian cancer	6.5e-05	0.000393	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—ovarian cancer	6.46e-05	0.000391	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—ovarian cancer	6.45e-05	0.00039	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—ovarian cancer	6.45e-05	0.00039	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—ovarian cancer	6.38e-05	0.000386	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—ovarian cancer	6.38e-05	0.000386	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—ovarian cancer	6.33e-05	0.000383	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—ovarian cancer	6.33e-05	0.000383	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—ovarian cancer	6.32e-05	0.000382	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—ovarian cancer	6.32e-05	0.000382	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—ovarian cancer	6.3e-05	0.000381	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—ovarian cancer	6.28e-05	0.00038	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—ovarian cancer	6.28e-05	0.00038	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—ovarian cancer	6.16e-05	0.000372	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—ovarian cancer	6.16e-05	0.000372	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—ovarian cancer	6.1e-05	0.000369	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—ovarian cancer	6.1e-05	0.000369	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—ovarian cancer	5.98e-05	0.000362	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—ovarian cancer	5.98e-05	0.000362	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—ovarian cancer	5.94e-05	0.000359	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—ovarian cancer	5.94e-05	0.000359	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.84e-05	0.000353	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—ovarian cancer	5.83e-05	0.000353	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—ovarian cancer	5.8e-05	0.000351	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—ovarian cancer	5.8e-05	0.000351	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—ovarian cancer	5.78e-05	0.000349	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—ovarian cancer	5.76e-05	0.000348	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—ovarian cancer	5.6e-05	0.000338	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—ovarian cancer	5.52e-05	0.000334	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—YAP1—ovarian cancer	5.38e-05	0.000325	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—ovarian cancer	5.37e-05	0.000325	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—ovarian cancer	5.37e-05	0.000325	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—ovarian cancer	5.37e-05	0.000325	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.32e-05	0.000322	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—ovarian cancer	5.31e-05	0.000321	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—ovarian cancer	5.31e-05	0.000321	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—ovarian cancer	5.3e-05	0.000321	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—ovarian cancer	5.3e-05	0.000321	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK1—ovarian cancer	5.25e-05	0.000318	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—ovarian cancer	5.25e-05	0.000317	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—ovarian cancer	5.08e-05	0.000307	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—ovarian cancer	5.08e-05	0.000307	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—ovarian cancer	4.96e-05	0.0003	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—ovarian cancer	4.94e-05	0.000299	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—ovarian cancer	4.94e-05	0.000299	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK1—ovarian cancer	4.83e-05	0.000292	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK1—ovarian cancer	4.83e-05	0.000292	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—ovarian cancer	4.83e-05	0.000292	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—ovarian cancer	4.83e-05	0.000292	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.68e-05	0.000283	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—ovarian cancer	4.56e-05	0.000276	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—ovarian cancer	4.56e-05	0.000276	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—ovarian cancer	4.56e-05	0.000276	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—ovarian cancer	4.41e-05	0.000267	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FASN—ovarian cancer	4.38e-05	0.000265	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A5—ovarian cancer	4.31e-05	0.000261	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—ovarian cancer	4.21e-05	0.000255	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—ovarian cancer	4.19e-05	0.000254	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—ovarian cancer	4.19e-05	0.000254	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A1—ovarian cancer	4.16e-05	0.000252	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.08e-05	0.000247	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—ovarian cancer	4.06e-05	0.000245	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—ovarian cancer	4.06e-05	0.000245	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—ovarian cancer	4.03e-05	0.000244	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1B1—ovarian cancer	3.99e-05	0.000241	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—ovarian cancer	3.88e-05	0.000235	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—ovarian cancer	3.88e-05	0.000235	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—ovarian cancer	3.72e-05	0.000225	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—ovarian cancer	3.71e-05	0.000225	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—ovarian cancer	3.71e-05	0.000225	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	3.54e-05	0.000214	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.52e-05	0.000213	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—ovarian cancer	3.42e-05	0.000207	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—ovarian cancer	3.42e-05	0.000207	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—ovarian cancer	3.29e-05	0.000199	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—ovarian cancer	3.23e-05	0.000195	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAV1—ovarian cancer	2.6e-05	0.000157	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.49e-05	0.00015	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.37e-05	0.000143	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.08e-05	0.000126	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.82e-05	0.00011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—ovarian cancer	1.57e-05	9.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.11e-05	6.7e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—ovarian cancer	9.04e-06	5.47e-05	CbGpPWpGaD
